MAP2K7 and neoplasm: We showed that AAG8 antagonist combined with very low concentration (50 nmol/L) of PD901 can significantly decrease the viability of refractory B16BR cells, suggesting that tandem AAG8-MEK inhibition is a powerful therapeutic approach for increasing the anti-tumor efficacy and decreasing the drug resistance of each single inhibitor.